IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v486y2012i7403d10.1038_nature11017.html
   My bibliography  Save this article

The landscape of cancer genes and mutational processes in breast cancer

Author

Listed:
  • Philip J. Stephens

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Patrick S. Tarpey

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Helen Davies

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Peter Van Loo

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
    Human Genome Laboratory, VIB and University of Leuven, Herestraat 49 Box 602, B-3000 Leuven, Belgium)

  • Chris Greenman

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
    School of Computing Sciences, University of East Anglia, Norwich NR4 7TJ, UK
    The Genome Analysis Centre, Norwich Research Park, Norwich NR4 7UH, UK)

  • David C. Wedge

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Serena Nik-Zainal

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Sancha Martin

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Ignacio Varela

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Graham R. Bignell

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Lucy R. Yates

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
    Breakthrough Breast Cancer Research Unit, Research Oncology, 3rd Floor Bermondsey Wing, Guy’s Hospital Campus, Kings College London School of Medicine, London SE1 9RT, UK
    Ground floor, Lambeth Wing, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London SE1 7EH, UK)

  • Elli Papaemmanuil

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • David Beare

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Adam Butler

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Angela Cheverton

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • John Gamble

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Jonathan Hinton

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Mingming Jia

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Alagu Jayakumar

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • David Jones

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Calli Latimer

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • King Wai Lau

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Stuart McLaren

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • David J. McBride

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Andrew Menzies

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Laura Mudie

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Keiran Raine

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Roland Rad

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Michael Spencer Chapman

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Jon Teague

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Douglas Easton

    (Centre for Cancer Genetic Epidemiology, Strangeways Research Laboratory, Cambridge CB1 8RN, UK
    Centre for Cancer Genetic Epidemiology, Strangeways Research Laboratory, Cambridge CB1 8RN, UK)

  • Anita Langerød

    (Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital)

  • Ming Ta Michael Lee

    (National Genotyping Center, Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Sec 2, Nankang, Taipei 115, Taiwan, China)

  • Chen-Yang Shen

    (National Genotyping Center, Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Sec 2, Nankang, Taipei 115, Taiwan, China)

  • Benita Tan Kiat Tee

    (Singapore General Hospital, 169608, Singapore)

  • Bernice Wong Huimin

    (NCCS-VARI Translational Research Laboratory, National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore)

  • Annegien Broeks

    (The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands)

  • Ana Cristina Vargas

    (The University of Queensland Centre for Clinical Research, The Royal Brisbane & Women’s Hospital, Herston, Brisbane, Queensland 4029, Australia)

  • Gulisa Turashvili

    (University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada
    Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia V5Z 1L3, Canada)

  • John Martens

    (Erasmus University Medical Center, Daniel den Hoed Cancer Center and Cancer Genomics Center, Postbus 2040, 3000 CA Rotterdam, Netherlands)

  • Aquila Fatima

    (Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA)

  • Penelope Miron

    (Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA)

  • Suet-Feung Chin

    (University of Cambridge and Cancer Research UK Cambridge Research Institute, Li Ka Shin Centre, Cambridge CB2 0RE, UK)

  • Gilles Thomas

    (Universite Lyon 1, INCa-Synergie, Centre Leon Berard, 28 rue Laennec, Lyon CEDEX 08, France)

  • Sandrine Boyault

    (Universite Lyon 1, INCa-Synergie, Centre Leon Berard, 28 rue Laennec, Lyon CEDEX 08, France)

  • Odette Mariani

    (Institut Curie, 26 rue d’Ulm, 75248 Paris CEDEX 05, France)

  • Sunil R. Lakhani

    (The University of Queensland Centre for Clinical Research, The Royal Brisbane & Women’s Hospital, Herston, Brisbane, Queensland 4029, Australia
    The University of Queensland School of Medicine, Herston Road, Herston, Brisbane, Queensland 4006, Australia
    Anatomical Pathology, Pathology Queensland, The Royal Brisbane and Women’s Hospital, Herston, Brisbane, Queensland 4029, Australia)

  • Marc van de Vijver

    (Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands)

  • Laura van ‘t Veer

    (The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands)

  • John Foekens

    (Erasmus University Medical Center, Daniel den Hoed Cancer Center and Cancer Genomics Center, Postbus 2040, 3000 CA Rotterdam, Netherlands)

  • Christine Desmedt

    (Breast Cancer Translational Laboratory, Université Libre de Bruxelles, Jules Bordet Institute, Boulevard de Waterloo 121, 1000 Brussels, Belgium)

  • Christos Sotiriou

    (Breast Cancer Translational Laboratory, Université Libre de Bruxelles, Jules Bordet Institute, Boulevard de Waterloo 121, 1000 Brussels, Belgium)

  • Andrew Tutt

    (Breakthrough Breast Cancer Research Unit, Research Oncology, 3rd Floor Bermondsey Wing, Guy’s Hospital Campus, Kings College London School of Medicine, London SE1 9RT, UK)

  • Carlos Caldas

    (University of Cambridge and Cancer Research UK Cambridge Research Institute, Li Ka Shin Centre, Cambridge CB2 0RE, UK
    NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK)

  • Jorge S. Reis-Filho

    (The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK)

  • Samuel A. J. R. Aparicio

    (University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada
    Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia V5Z 1L3, Canada)

  • Anne Vincent Salomon

    (Institut Curie, 26 rue d’Ulm, 75248 Paris CEDEX 05, France
    Institut Curie, INSERM Unit 830, 26 rue d’Ulm, 75248 Paris CEDEX 05, France)

  • Anne-Lise Børresen-Dale

    (Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital
    K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo)

  • Andrea L. Richardson

    (Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA
    Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115, USA)

  • Peter J. Campbell

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
    Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    University of Cambridge, Hills Road, Cambridge CB2 2XY, UK)

  • P. Andrew Futreal

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

  • Michael R. Stratton

    (Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK)

Abstract

A study of breast cancers shows that the number of somatic mutations in each varies markedly and is strongly correlated with age at diagnosis and cancer histological grade.

Suggested Citation

  • Philip J. Stephens & Patrick S. Tarpey & Helen Davies & Peter Van Loo & Chris Greenman & David C. Wedge & Serena Nik-Zainal & Sancha Martin & Ignacio Varela & Graham R. Bignell & Lucy R. Yates & Elli , 2012. "The landscape of cancer genes and mutational processes in breast cancer," Nature, Nature, vol. 486(7403), pages 400-404, June.
    • Handle: RePEc:nat:nature:v:486:y:2012:i:7403:d:10.1038_nature11017
    DOI: 10.1038/nature11017
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature11017
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature11017?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Zhe Jiang & YoungJun Ju & Amjad Ali & Philip E. D. Chung & Patryk Skowron & Dong-Yu Wang & Mariusz Shrestha & Huiqin Li & Jeff C. Liu & Ioulia Vorobieva & Ronak Ghanbari-Azarnier & Ethel Mwewa & Maria, 2023. "Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    2. Karama Asleh & Gian Luca Negri & Sandra E. Spencer Miko & Shane Colborne & Christopher S. Hughes & Xiu Q. Wang & Dongxia Gao & C. Blake Gilks & Stephen K. L. Chia & Torsten O. Nielsen & Gregg B. Morin, 2022. "Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    3. Lukas John & Alexandra M. Poos & Alexander Brobeil & Carolina Schinke & Stefanie Huhn & Nina Prokoph & Raphael Lutz & Barbara Wagner & Maurizio Zangari & Stephan M. Tirier & Jan-Philipp Mallm & Sabrin, 2023. "Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    4. Leo Rasche & Carolina Schinke & Francesco Maura & Michael A. Bauer & Cody Ashby & Shayu Deshpande & Alexandra M. Poos & Maurizio Zangari & Sharmilan Thanendrarajan & Faith E. Davies & Brian A. Walker , 2022. "The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    5. Luan Nguyen & Arne Hoeck & Edwin Cuppen, 2022. "Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    6. Stéphanie Cornen & Arnaud Guille & José Adélaïde & Lynda Addou-Klouche & Pascal Finetti & Marie-Rose Saade & Marwa Manai & Nadine Carbuccia & Ismahane Bekhouche & Anne Letessier & Stéphane Raynaud & E, 2014. "Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-16, January.
    7. S. Mouron & M. J. Bueno & A. Lluch & L. Manso & I. Calvo & J. Cortes & J. A. Garcia-Saenz & M. Gil-Gil & N. Martinez-Janez & J. V. Apala & E. Caleiras & Pilar Ximénez-Embún & J. Muñoz & L. Gonzalez-Co, 2022. "Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    8. Yanis Tazi & Juan E. Arango-Ossa & Yangyu Zhou & Elsa Bernard & Ian Thomas & Amanda Gilkes & Sylvie Freeman & Yoann Pradat & Sean J. Johnson & Robert Hills & Richard Dillon & Max F. Levine & Daniel Le, 2022. "Unified classification and risk-stratification in Acute Myeloid Leukemia," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:486:y:2012:i:7403:d:10.1038_nature11017. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.